Medtronic makes two key additions to its board. How activist Elliott can build shareholder value
1. Medtronic appoints new directors in response to Elliott's engagement. 2. Formed Growth and Operating Committees to stimulate growth and improve margins. 3. Recent product developments may enhance long-term growth prospects. 4. Company's stock underperformed, with low revenue growth over the past decade. 5. Spinoff of diabetes business expected within 15 months to focus on core operations.